Search results
Results from the WOW.Com Content Network
An editorial article on the paper indicated that researchers had observed dopaminergic neurotoxicity (death of neurons involved in dopamine pathways) in monkeys following MDMA injections, a finding which suggested that recreational users of MDMA may be at risk of developing neuropsychiatric disorders associated with dopamine dysfunction. [3]
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.
[121] [122] [123] Similarly, norepinephrine–dopamine reuptake inhibitors (NRIs) like methylphenidate and bupropion prevent norepinephrine and dopamine release induced by amphetamines and bupropion has been found to reduce the subjective and sympathomimetic effects of methamphetamine in humans.
3,4-Dihydroxymethamphetamine (HHMA, 3,4-DHMA), or 3,4-dihydroxy-N-methylamphetamine, also known as α-methylepinine or α,N-dimethyldopamine, is the major metabolite of 3,4-methylenedioxy-N-methylamphetamine (MDMA).
Amphetamine, an NDRA and one of the most well-known DRAs. 4-Methylaminorex (4-MAR), the cis- isomer being one of the most dopamine-selective NDRAs known.. A dopamine releasing agent (DRA) is a type of drug which induces the release of dopamine in the body and/or brain.
[3] [4] [5] Methamphetamine psychosis, or long-term effects of stimulant use in the brain (at the molecular level), depend upon genetics and may persist for months or years. [6] Psychosis may also result from withdrawal from stimulants, particularly when psychotic symptoms were present during use. [7]
MDMA was also found to have effects on blood sugar levels comparable to high doses of ephedrine. Oberlin concluded that the effects of MDMA were not limited to the sympathetic nervous system. Research was stopped "particularly due to a strong price increase of safrylmethylamine", which was still used as an intermediate in methylhydrastinine ...
Amphetamines causes an increase in dopamine release, which is the proposed mechanism for its wake-promoting effect. [18] ATS such as dextroamphetamine are used in the treatment of narcolepsy when another CNS stimulant, modafinil is not effective. [19]